UCB SA (UCBJY)
OTCMKTS
· Delayed Price · Currency is USD
99.97
+2.62 (2.69%)
Dec 23, 2024, 4:00 PM EST
UCB SA Revenue
UCB SA had revenue of 2.79B EUR in the half year ending June 30, 2024, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 5.45B, up 3.32% year-over-year. In the year 2023, UCB SA had annual revenue of 5.18B, down -4.87%.
Revenue (ttm)
5.45B EUR
Revenue Growth
+3.32%
P/S Ratio
n/a
Revenue / Employee
600.46K EUR
Employees
9,083
Market Cap
37.33B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
Dec 31, 2019 | 4.91B | 281.00M | 6.07% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
UCB SA News
- 21 days ago - United Community Banks to acquire ANB Holdings in an all-stock deal - Seeking Alpha
- 4 weeks ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 4 weeks ago - FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease - Benzinga
- 4 weeks ago - UCB gets FDA approval for Bimzelx for hidradenitis suppurativa - Seeking Alpha
- 5 weeks ago - Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - Seeking Alpha
- 6 weeks ago - United Community Banks: Too Rich For My Blood - Seeking Alpha
- 2 months ago - Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy - Seeking Alpha
- 3 months ago - UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 - Benzinga